Alejandro González Veliz: How Plaque Morphology Shapes PCI Outcomes
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn:
”Same stent. Different plaque. Different outcome.
Does plaque morphology matter after PCI?
A new substudy of ILUMIEN IV evaluated preprocedural OCT-defined plaque morphology and its association with procedural and clinical outcomes after PCI.
Among 926 patients with a single de novo lesion, plaques were classified as predominantly lipidic, calcific, or fibrotic based on OCT.
The findings were striking:
- 🔹 Calcific plaques had the lowest stent expansion and the highest 2-year target-vessel failure (TVF).
- 🔹 Fibrotic plaques had the lowest clinical event rate.
- 🔹 Lipidic plaques achieved the greatest acute luminal gain, but their 2-year clinical risk was intermediate.
At 2 years, TVF occurred in:
10.7 percent — Calcific
5.6 percent — Lipidic
4.0 percent — Fibrotic
For calcific vs fibrotic lesions, the adjusted HR for TVF was 2.20 (95 percent CI 1.12–4.33; P equals zero point zero twoՃ, driven primarily by increased ischemia-driven target-vessel revascularization.
The message is not that plaque morphology alone determines outcome.
Rather, OCT may provide information about lesion biology and mechanical behavior that angiography cannot fully capture—information that can influence lesion preparation, stent deployment, expansion, and optimization.
One important caveat: this was a secondary analysis of the OCT-guided arm of ILUMIEN IV, so these findings demonstrate an association rather than proving that plaque phenotype itself causes worse outcomes.
Know the plaque. Optimize the PCI.”

Stay updated with Hemostasis Today.
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia
-
Aug 23, 2026, 10:10Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:03Balaji Balagani: Major Causes of Sudden Cardiac Death in Children
-
Aug 23, 2026, 16:02Bartosz Hudzik: What’s Hot at ESC Congress 2026
-
Aug 23, 2026, 16:01Jim Hoffman: NETs in STEMI and Their Association With PCI and Antithrombotic Treatments
-
Aug 23, 2026, 16:01Luis Oliverio Ambriz Garcia: Key Insights Into Myeloproliferative Neoplasms From the 2026 NEJM Review
-
Aug 23, 2026, 15:58Howard Smith: Automated MR Imaging Aids New Stroke Therapy Development